Wellington Management Group LLP Sells 8,552 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Wellington Management Group LLP lowered its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 136,795 shares of the company's stock after selling 8,552 shares during the quarter. Wellington Management Group LLP owned approximately 0.36% of Tarsus Pharmaceuticals worth $7,574,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $25,000. GF Fund Management CO. LTD. bought a new position in Tarsus Pharmaceuticals during the fourth quarter worth $44,000. Quarry LP acquired a new position in shares of Tarsus Pharmaceuticals in the fourth quarter valued at $166,000. HighTower Advisors LLC bought a new position in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $207,000. Finally, Summit Investment Advisors Inc. lifted its stake in shares of Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after buying an additional 244 shares during the last quarter. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Trading Down 0.5%

Shares of TARS traded down $0.22 during mid-day trading on Friday, reaching $43.87. 394,361 shares of the company were exchanged, compared to its average volume of 701,439. The business has a 50 day simple moving average of $46.32 and a two-hundred day simple moving average of $48.87. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market capitalization of $1.84 billion, a PE ratio of -11.52 and a beta of 0.83. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. The firm had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 2,137 shares of the firm's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $107,085.07. Following the transaction, the insider now directly owns 46,355 shares of the company's stock, valued at approximately $2,322,849.05. This trade represents a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $154,654.89. Following the transaction, the general counsel now owns 58,057 shares of the company's stock, valued at $2,687,458.53. This represents a 5.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock valued at $1,581,173 in the last three months. Corporate insiders own 8.97% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on TARS shares. The Goldman Sachs Group boosted their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Guggenheim raised their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Barclays lowered their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Oppenheimer initiated coverage on Tarsus Pharmaceuticals in a research report on Monday. They issued an "outperform" rating and a $75.00 target price on the stock. Finally, HC Wainwright raised Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price for the company in a research note on Tuesday, May 27th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $66.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.